Press Detail





News: Biotest AG: Biotest takes over Cara Plasma s.r.o. with one plasma collection centre in the Czech Republic

News: Biotest AG / Key word(s): Miscellaneous
Biotest AG: Biotest takes over Cara Plasma s.r.o. with one plasma collection
centre in the Czech Republic

19.07.2017 / 07:00
The issuer is solely responsible for the content of this announcement.



PRESS RELEASE

Biotest takes over Cara Plasma s.r.o. with one plasma collection centre in
the Czech Republic

- Long-term plasma supplier Cara Plasma was taken over by Biotest

- Biotest has now 16 plasma collection centres in Europe and

- 22 stations in the USA for the strategic safeguarding of plasma supply


Dreieich, 19 July 2017. Today, Biotest took over its long-time plasma
supplier Cara Plasma s.r.o. and thus increased the number of plasma centres
in Europe to 16.

With Cara Plasma Biotest purchased a station in the Czech capital Prague and
will further increase the plasma self-sufficiency rate.

"The additional station in the Czech Republic gives us the opportunity to
secure the supply for our production facilities with plasma. We are raising
the good and trustworthy cooperation with our long-term partner and current
supplier Cara Plasma to a new stage." stated Dr. Martin Reinecke, Head of
Plasma Alliances and Protein Supply.

The collected plasma is processed exclusively at Biotest AG, Dreieich,
Germany. Audits conducted regularly in the Czech Republic ensure that high
legal and internal quality requirements are met.

Biotest's strategic goal is to increase the share of plasma from its own
centres in the future. At the same time Biotest is striving for a balanced
supply of plasma from Europe and the USA.

About human blood plasma
Human blood plasma is a raw material used to produce plasma derived
products, which are used to treat various illnesses of the immune system,
the blood system, as well as in emergency medicine. Biotest ranks as one of
the world's sixth largest plasma protein product manufacturing groups.
Biotest is one of the world's six largest manufacturers of plasma protein
products.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 2,500
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich,
Stuttgart

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.




19.07.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de



Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange



End of News DGAP News Service


593617 19.07.2017